Anthem Biosciences IPO GMP & Review: Apply or Avoid?

Posted by : sachet | Fri Jul 11 2025

Anthem Biosciences IPO GMP & Review: Apply or Avoid?

Anthem Biosciences IPO is open for bidding on 14th July 2025. It is a book-building IPO of 5.96 crore shares worth ₹3,395.00 crores. It is entirely a fresh issue. The issue will be listed on BSE and NSE on its tentative listing date, 21st July 2025. 

Anthem Biosciences IPO Details

The Anthem Biosciences IPO date is fixed between 14th July 2025 and 16th July 2025. The face value of Anthem Biosciences Limited shares stands at ₹10 per share, and the IPO price band is fixed at ₹540 to ₹570 per share. 

Kfin Technologies Limited is the registrar of the Anthem Biosciences IPO and is responsible for managing the allotment process and initiating refunds. Check out the latest IPO details in the table below. 

IPO Open Date14th July 2025
IPO Close Date16th July 2025
IPO Allotment Date17th July 2025
Refund Initiation 18th July 2025
Issue Size5,95,61,404 shares (worth ₹3,395.00 crore)
Face Value₹2 per share
Lot Size26 shares
Issue Price Band₹540 to ₹570 per share
Issue TypeOffer for Sale IPO
Listing AtBSE & NSE
Listing Date21st July 2025

Anthem Biosciences IPO Share Reservation

Anthem Biosciences IPO is a bookbuilding IPO issue of 5.96 crore shares worth ₹3,395.00 crores. Anthem Biosciences Limited shares will be listed on the BSE and NSE. Furthermore, SEBI has specified the share reservation criteria for different investor categories. 

Investor CategoriesReservation Required 
QIB Shares OfferedNot more than 50.00% of the net issue
Retail Shares OfferedNot less than 35.00% of the net issue
NII (HNI) Shares OfferedNot less than 15.00% of the net issue
Total Shares Offered100%

Click here to download Smartworks Coworking Spaces RHP for detailed information.

Anthem Biosciences IPO GMP Grey Market Premium

GMP is the gap between the price band of the issue and the price at which company shares are currently trading in the grey market. Do you want to get live updates on the Anthem Biosciences IPO? If yes, then you’ve reached the right spot. Check the table below to learn about the GMP trends.

GMP DateIPO PriceGMPEstimated Listing Price Estimated Listing Gains
11-07-2025₹570₹108₹67818.94%
10-07-2025₹570₹97₹66717.01%
09-07-2025₹570₹67₹63711.75%
08-07-2025₹570₹75₹64513.15%
07-07-2025₹570₹0₹5700.00%
06-07-2025₹570₹0₹5700.00%
05-07-2025₹570₹0₹5700.00%
04-07-2025₹570₹0₹5700.00%
03-07-2025₹570₹0₹5700.00%

As of 11th July 2025, Anthem Biosciences IPO GMP stands at ₹29 per share, which means the share will likely show a listing at ₹436 (407+29) on its tentative listing date, 21st July 2025.

GMP data is subject to change based on market trends and sentiments. You should check the live GMP status before applying for the Anthem Biosciences IPO

Stay updated on Univest to know about live IPOs and their GMP trends! 

Anthem Biosciences IPO Review

Check out the detailed Anthem Biosciences IPO review for a thorough understanding of its potential to report listing gains on 21st July 2025. The Anthem Biosciences IPO review below will help you invest effectively to avoid significant losses. Explore more to make informed investment decisions on this IPO. 

Financial Health

Assess a company’s financial performance to know about its ability to sustain a competitive edge. Thus, it is essential to understand the growth margins and declines of the business’s financials before applying for the Anthem Biosciences IPO.

Anthem Biosciences Limited’s revenue rose 30.15% from ₹1,483.07 crores in March 2024 to ₹1,930.29 crores in March 2025. Moreover, the company’s PAT increased by 22.85% from ₹367.31 crores to ₹451.26 crores. 

Anthem Biosciences Limited has shown consistent revenue growth, indicating that the company is financially stable. Moreover, the brokers, investors, and RAs have a positive outlook for the Anthem Biosciences IPO for its tentative listing day, which is 21st July 2025.  

Technical Analysis

A number of technical indicators are available to assess a company’s potential to deliver returns. Use the parameters mentioned below to analyse the technicals of the Anthem Biosciences IPO.

Key IndicatorsValue
PE Ratio (Price-to-Earnings) 70.62
EPS (Earnings Per Share)8.07
RoNW20.82%
ROE (Return on Equity)20.82%
ROCE26.88%
EBITDA Margin36.81%
Price to Book Value13.23
PAT Margin23.38

The PE ratio of Anthem Biosciences Limited shares is 70.62, and its Earnings Per Share (EPS) stands at 8.07. Thus, the Anthem Biosciences IPO can potentially deliver gains on its tentative listing date, 21st July 2025. 

Note: The data, as mentioned above, is taken from authentic sources and highlights pre-issue information. The PE ratio and EPS of Anthem Biosciences Limited are subject to change after the IPO. Explore the table below to get post-issue updates on these two metrics. 

IndicatorsPre-IPOPost-IPO
PE Ratio70.6270.62
EPS 8.078.07

Anthem Biosciences Limited Peer Comparison

Company NameRevenue (in cr.)PE RatioFace Value (in Rs)EPS RoNW (in %)
Anthem Biosciences Limited1,930.2970.6228.0720.82%
Syngene International Limited3,714.0051.541012.3411.05%
Sai Life Sciences Limited1,494.0092.1818.6110.96%
Cohance Lifesciences Limited1,113.0097.29110.4513.61%
Divi’s Laboratories Limited8,184.0083.22282.5315.35%

Anthem Biosciences IPO Subscription Status

Anthem Biosciences IPO is to be opened for bidding on 14th July 2025. The subscription status for this IPO is yet to be announced. Stay informed on this passage to check the live Anthem Biosciences IPO Subscription Status. 

Investor CategoryShares OfferedShares SubscribedSubscription in Times
Retail InvestorsYet to be announcedYet to be announcedYet to be announced
QIBYet to be announcedYet to be announcedYet to be announced
NII (sNII+bNII)Yet to be announcedYet to be announcedYet to be announced
TotalYet to be announcedYet to be announcedYet to be announced

About Anthem Biosciences Limited

Anthem Biosciences Limited was incorporated in 2006 and is an innovation-driven, technology-focused contract research organisation with fully integrated operations. The company serves diverse customers, including innovative, emerging biotech firms and large pharmaceutical companies on a global scale. As of September 30 2024, the company had 196 projects: 170 discovery projects (284 synthesised molecules), 132 early phase projects, 16 late phase projects (10 late phase molecules), and 13 commercial manufacturing projects (API and intermediates for 10 commercialised molecules). Here are the major competitive strengths of Anthem Biosciences Limited.

  • One-stop service across the drug life cycle (discovery, development, manufacturing) for small molecules and biologics; we are India’s fastest growing CRDMO.
  • Innovation-focused approach has enabled us to offer a spectrum of technologically advanced solutions across modalities and manufacturing practices.
  • Specialised business model for small pharmaceutical and biotech companies, from discovery to manufacturing.
  • Long-standing relationships with a large, diversified and loyal customer base.
  • Professional and experienced leadership team supported by a qualified scientific talent pool.

Anthem Biosciences Limited Financials

The company’s financial analysis is essential before applying for the Anthem Biosciences IPO. Look at the table to learn about Anthem Biosciences Limited’s financials. 

Year Ended31st March 2025 (in cr.)31st March 2024 (in cr.)31st March 2023 (in cr.)
Assets2,807.582,398.112,014.46
Revenue1,930.291,483.071,133.99
Profit After Tax451.26367.31385.19
Debt108.95232.53125.06
Reserves and Surplus2,298.051,815.391,628.88
Net Worth2,409.861,924.661,740.67

Explanation

Anthem Biosciences Limited’s revenue rose 30.15% from ₹1,483.07 crores in March 2024 to ₹1,930.29 crores in March 2025. Moreover, the company’s PAT increased by 22.85% from ₹367.31 crores to ₹451.26 crores. 

Anthem Biosciences IPO Bidding Requirements

Anthem Biosciences IPO has reserved lot sizes to be applied by different investor categories. Look at the table below to know about the requirements to be fulfilled for applying for this IPO. 

Investor CategoryLotsSharesAmount (in Rs)
Retail (Minimum)126 shares₹14,820
Retail (Maximum)13338 shares₹1,92,660
S-HNIs (Minimum)14364 shares₹2,07,480
S-HNI (Maximum)681,742 shares₹9,92,940
B-HNI (Minimum)691,768 shares₹10,07,760

Use the lot size calculator to find how many shares you should apply!

Anthem Biosciences IPO Promoter Holdings

Have a look at the table below to check the holdings of Anthem Biosciences Limited’s promoters: Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa, and Ishaan Bhardwaj. 

Share Holding Pre-Issue76.87%
Share Holding Post-Issue74.68%

Note: Promoter Holdings’ value is to be calculated using Equity dilution, which represents the gap between shareholdings before and after the Issue. 

Aim of Anthem Biosciences IPO

Anthem Biosciences Limited will not receive any proceeds from this offer for sale and all the proceeds will be received by the selling shareholders. 

Should I Invest in Anthem Biosciences IPO?

ABL is one of the leading global players in innovation driven, technology focused CRDMO segment. It enjoys niche place in the segment and leads the pack of players. The company marked steady growth in its top lines for the reported periods. Higher net for FY23 is attributed to exceptional income adjustment for the said year. Though prima-facie the issue appears aggressively priced, investors may park funds for long term.”~Dilip Davda (Chief Editor at Chittorgarh)

Explore the pros and cons of Anthem Biosciences IPO to know whether you should apply or avoid the issue. These pros and cons might help you know about the IPO’s efficiency in delivering profits in the coming decades. 

Pros of Anthem Biosciences IPO

  • Innovation Focused Approach
  • Long-Standing Customer Relationship 

Cons of Anthem Biosciences IPO

No Consequences

How to Apply for Anthem Biosciences IPO?

Check the steps mentioned below to apply for the Anthem Biosciences IPO

  • Step 1: Conduct thorough research on Anthem Biosciences IPO GMP, subscription status, issue size, lot size, and other details. 
  • Step 2: Open a demat account on Univest to learn about real-time insights on GMP and subscription status. You can also use your previous demat account by navigating to the IPO section. 
  • Step 3: Make a bid for 1 lot of 26 shares worth ₹14,820 of Anthem Biosciences IPO.   
  • Step 4: You will receive a mandate request after making a bid. Approve the request to proceed further.    

Note: You can apply for the Anthem Biosciences IPO from more than one demat account to increase your allotment chances. 

Also Read : Valencia India IPO GMP & Review: Apply or Avoid?

How to Check Anthem Biosciences IPO Allotment Status?

You can check for Anthem Biosciences IPO allotment in different ways. These include NSE and the registrar portal. Look at the steps mentioned below to check your allotment status online.

Check On NSE

  • Visit the NSE Official Website.
  • Navigate to the IPO Allotment Section. 
  • Select Equity as the issue type. 
  • Choose Anthem Biosciences IPO.  
  • Choose whether to proceed with the PAN number or the application number.
  • Submit your details to get the allotment status online. 

Check On the Registrar Portal

  • Visit the registrar portal
  • Click on the allotment option.
  • Fill in the required details.
  • Click on the submit button to know your Anthem Biosciences IPO allotment status.

Let’s Wrap

Anthem Biosciences IPO is a book-building issue of 5.96 crore shares worth ₹3,395.00 crores. The shares of Anthem Biosciences Limited will be listed on NSE and BSE on its tentative listing date of 21st July 2025. Researching the Anthem Biosciences IPO GMP and reviews is highly suggested to book your ideal profitability. Brokers and investors have highlighted their pros and cons, so one must analyse them and decide accordingly.

Open a demat account on Univest now to initiate your investment journey!

FAQs on Anthem Biosciences IPO

How is the Anthem Biosciences IPO?

Ans. Currently, on 11th July 2025, Anthem Biosciences IPO GMP (Grey Market Premium) stands at ₹29 (7.12% up). It indicates that the estimated listing price could be ₹436 per share. It is a book building IPO of 5.96 crore shares worth ₹3,395.00 crores. The face value of each share of Anthem Biosciences Limited is ₹2. 

What is the Anthem Biosciences IPO price?

Ans. Anthem Biosciences IPO price band has been set between ₹540 and ₹570 per share. Retail investors can apply for a minimum of 1 lot consisting of 26 shares worth ₹14,820. Moreover, HNIs are required to bid for a minimum of 13 lots (338 shares) worth ₹1,92,660. 

Is the Anthem Biosciences IPO good?

Ans. Anthem Biosciences Limited’s revenue rose 30.15% from ₹1,483.07 crores in March 2024 to ₹1,930.29 crores in March 2025. Moreover, the company’s PAT increased by 22.85% from ₹367.31 crores to ₹451.26 crores. Investors can analyse other relevant factors and make a decision accordingly.

Who is the registrar of the Anthem Biosciences IPO?

Ans. Kfin Technologies Limited is the registrar of the Anthem Biosciences IPO, awaiting to manage the IPO allotment procedure and refund initiation. For any queries regarding the Anthem Biosciences IPO allotment and refund, you can contact Kfin Technologies Limited at reachus@kfintech.com or 04067162222.

What is the issue size of the Anthem Biosciences IPO? 

Ans. Anthem Biosciences IPO is a book-building IPO for 5.96 crore shares worth ₹3,395.00 crore. Moreover, the IPO is set to open on 14th July 2025 and will close on 16th July 2025. 

Disclaimer: The above information is compiled from authentic sources and is just for informational purposes. To have detailed information about the Anthem Biosciences IPO, download the Anthem Biosciences IPO RHP and Anthem Biosciences IPO DRHP. Conduct your own research before investing in IPOs to avoid significant losses. You can also consult your financial advisor.

Upcoming IPOs

CompanyType
NSDL IPOMainboard
Flipkart IPOMainboard
National Stock Exchange IPOMainboard
JSW Cement IPOMainboard
boAt IPOMainboard
Zepto IPOMainboard

Current & Previous IPOs

CompanyIPO OpenIPO CloseType
Asston Pharmaceuticals Limited9th July 202511th July 2025SME
GLEN Industries Limited8th July 202510th July 2025SME
Travel Food Services Limited7th July 20259th July 2025Mainboard
Chemkart India Limited7th July 20259th July 2025SME
Smarten Power Systems Limited7th July 20259th July 2025SME
Meta Infotech Limited4th July 20258th July 2025SME
Cryogenic OGS Limited3rd July 20257th July 2025SME
Happy Square Outsourcing Services Limited3rd July 20257th July 2025SME
Crizac Limited3rd July 20257th July 2025Mainboard
Silky Overseas Limited30th June 20252nd July 2025SME
Pushpa Jewellers Limited30th June 20252nd July 2025SME
Cedaar Textile Limited30th June 20252nd July 2025SME
Marc Loire Fashions Limited30th June 20252nd July 2025SME
Vandan Foods Limited30th June 20252nd July 2025SME
Neetu Yoshi Limited27th June 20251st July 2025SME
Indogulf Cropsciences Limited26th June 202530th June 2025Mainboard
PRO FX Tech Limited26th June 202530th June 2025SME
Adcounty Media India Limited26th June 202530th June 2025SME

Read Our Articles on the Best Stocks

Tech Stocks in India to Invest in 2025 | Tech Sector Stocks 

Best Battery Stocks in India to Invest in 2025 | Battery Sector Stocks 

Best Shipping Stocks in India to Invest in 2025 | Shipping Sector Stocks 

Paint Stocks in India to Invest in 2025 | Paint Sector Stocks 

Paper Stocks in India to Invest in 2025 | Paper Sector Stocks 

Best Semiconductor Stocks in India 2025 

Best Large Cap Stocks in India 2025 

Green Energy Penny Stocks

Best Cement Stocks To Invest in India

Also Explore

Best Stocks Multibagger Stocks Penny StocksFundamentally Strong Stocks Sector Wise StocksPSU /Government Stocks
For Next 10 YearsFor Next 5 YearsSolar Penny StocksOn BSESolar Energy SectorPSU Stocks List
Long Term Below 100 rsTop 5 Penny StocksFor Long-TermHospitality Sector PSU Stocks in 2025
Best Bike StocksFor 2025Best Penny Stocks in IndiaPenny SharesHotel SectorGovernment Stocks in 2024
Best Liquor StocksHigh Growth StocksFor 2025Agriculture SectorGovernment Stocks List
Best Railway StocksUnder 500Penny Stocks Pharma SectorGovernment Stocks in 2025
Best Auto StocksFor 2026Oil and Gas Sector

Univest Screeners

ExclusiveIndicesBreakouts
Buy in Short TermNifty Small Cap 100Daily Fresh Breakouts
Buy in Long TermNifty MidcapWeekly Breakouts
FII Holdings ChangeNifty BankOversold Stocks
Golden CrossoverSensexNearing Breakout
Upcoming DividendsNifty Fin Service
DII Holdings ChangeBankex
High Dividend StocksNifty Mid Cap 100
Earnings AnnouncedNifty 50
Fundamentally Strong 
Top Gainers
Top Losers
Low Debt Mid Caps
Cash-Rich Small Caps
Volume Shockers
52-Week High 
52-Week Low

Explore Webstories on Univest 

1. Best Time To Buy Dividend Stocks

2. How RBI Policies Affect Dividend Stocks

3. Can Dividend Stocks Beat Inflation

4. What Is The Dividend Aristocrat List

5. Which Indian Psus Offer The Best Dividends

6. Large Cap Vs Small Cap Dividend Stocks

icon

100% Safe & Secure Platform.

Univest encrypts all data and transactions to ensure a completely secure experience for our members.

Copyright

2025 Univest. All rights reserved. | Designed with ❤️ in India
About Univest
About: Univest is a cutting-edge stock market platform designed to help traders and investors maximize their returns with expert-driven advisory services and seamless trading execution. Whether you're a seasoned trader or just starting, Univest simplifies your investment journey with actionable trade recommendations, AI-powered portfolio insights, and a fully integrated brokerage experience. With Univest, you gain access to proven stock market advisory, offering expert trade ideas for stocks, futures, options, and commodities. Our one-click trade execution feature eliminates slippage, ensuring instant execution through our advisory-first brokerage. Smart portfolio management allows you to identify underperforming stocks, optimize your investments, and receive real-time alerts. Additionally, Univest provides seamless investment opportunities beyond stocks, including mutual funds, bonds, fixed deposits, and insurance (coming soon). Join over 40 lakh active investors who trust Univest to make informed and profitable trading decisions. Start investing smarter today! 🚀  
Attention Investors : To ensure a smooth trading experience and prevent unauthorized transactions, investors must update their mobile number and email ID with their stockbroker or depository participant. As per regulatory requirements, investors are required to pay a stipulated amount as an upfront margin for trading in the Cash/FO segment. We encourage all investors to regularly check their securities in the Consolidated Account Statement (CAS) issued by depository to verify their holdings.Always verify alerts and transaction details received directly from the exchange or NSDL before proceeding with any trades. Please do not make payments through unverified email links, WhatsApp, or SMS. Always trade through a registered stockbroker and verify all details before making financial decisions.
 
Disclaimer: Investments in the securities market are subject to market risks. Please read all related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit. For more disclaimer /disclosure, visit https://univest.in/stock-broker or Univest App.We collect and use your contact information for legitimate business purposes, including providing updates on our products and services. We do not sell or rent your contact information to third parties. By submitting your details, you authorize us to contact you via Call/SMS, even if you are registered under DND. This authorization remains valid for 12 months.For grievances, please contact us at hello@unibrokers.in .
 
Univest Stock Broking Disclosures
Univest Stock Broking Private Limited - SEBI Reg. No. INZ000317437 (Stock Broker), NSE TM Code: 90392, BSE TM Code: 6866, MCX TM Code: 57290 and ICCL- Self Clearing Member Code: 6866, SEBI Reg. No. IN-DP-779-2024 (Participant), NSDL DP ID: IN304748.
 Risk Disclosures on Derivatives
1. 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
2. On an average, loss makers registered net trading loss close to ₹ 50,000
3. Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
4. Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Attention Investors: As per NSE circular dated July 6, 2022: https://nsearchives.nseindia.com/content/circulars/INSP52900.pdf, BSE circular dated July 6, 2022: https://www.bseindia.com/markets/MarketInfo/DispNewNoticesCirculars.aspx?page=20220706-55, MCX circular dated July 11, 2022: https://www.mcxindia.com/docs/default-source/circulars/english/2022/july/circular-418-2022.pdf?sfvrsn=9401991_0, investors are cautioned to abstain them from dealing in any schemes of unauthorised collective investments/portfolio management, indicative/ guaranteed/fixed returns / payments etc. 
Investors are further cautioned to avoid practices like:
a. Sharing 
i) trading credentials – login id and passwords including OTPs.
ii) trading strategies,
iii) position details.
b. Trading in leveraged products /derivatives like Options without proper understanding, which could lead to losses.
c. Writing/ selling options or trading in option strategies based on tips, without basic knowledge and understanding of the product and its risks.
d. Dealing in unsolicited tips through platforms like Whatsapp, Telegram, Instagram, YouTube, Facebook, SMS, calls, etc.
e. Trading / Trading in “Options” based on recommendations from unauthorised / unregistered investment advisors and influencers.
 Kindly read the Advisory Guidelines For Investors as prescribed by the Exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client’s assets: https://nsearchives.nseindia.com/content/circulars/INSP49434.pdf
Kindly, read the advisory as prescribed by the Exchange with reference to their circular: NSE/ISC/51035 dated January 14, 2022 regarding Updation of mandatory KYC fields by March 31, 2022: https://www.nseindia.com/resources/exchange-communication-circulars# 
Attention Investors: Prevent unauthorised transactions in your Demat account by updating your mobile number with your depository participant. Receive alerts on your registered mobile number for debit and other important transactions in your Demat account directly from NSDL on the same day. Prevent unauthorised transactions in your Trading account by updating your mobile numbers/email addresses with your stock brokers. Receive information on your transactions directly from the Exchange on your mobile/email at the end of the day. Issued in the interest of investors. KYC is a one-time exercise while dealing in securities markets - once KYC is done through a SEBI-registered intermediary (Broker, DP), you need not undergo the same process again when you approach another intermediary. As a business, we don’t give stock tips and have not authorised anyone to trade on behalf of others. If you find anyone claiming to be part of Univest Stock Broking Private Limited and offering such services, please send us an email at hello@unibrokers.in
No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor’s account.
Update your email ID and mobile number with your stockbroker/depository participant and receive an OTP directly from the depository on your registered email ID and/or mobile number. Check your securities/mutual funds/bonds in the Consolidated Account Statement (CAS) issued by NSDL every month.
Attention Investors: SEBI has established an Online Dispute Resolution Portal (ODR Portal) for resolving disputes in the Indian Securities Market. This circular streamlines the existing dispute resolution mechanism, offering online conciliation and arbitration, benefiting investors and listed companies https://www.sebi.gov.in/legal/circulars/jul-2023/online-resolution-of-disputes-in-the- indian-securities-market_74794.html. ODR portal for Investors - https://smartodr.in/login.
Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances.
General
arrow down